Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to 'Single-cell evidence for PANoptosome complexes'.

Nature reviews. Molecular cell biology·2026
Same author

Infection-induced glucose starvation triggers NINJ1-dependent macrophage lysis and Candida escape.

Nature communications·2026
Same author

The benchmarking and application of tag-degraders in vivo to validate therapeutic targets.

Nature communications·2026
Same author

The transmembrane domain structure of TNFR1 suppresses ligand-independent autoactivation but is not required for TNF-induced signaling.

Science signaling·2026
Same author

Hemidesmosomal Proteins in Oral Cancer Progression: An Immunohistochemical Study of Human and Mouse.

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·2026
Same author

The PANoptosis hypothesis examined.

Nature reviews. Molecular cell biology·2026

Related Experiment Video

Updated: Dec 28, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.6K

Future Therapeutic Directions for Smac-Mimetics.

Emma Morrish1,2, Gabriela Brumatti1,2, John Silke1,2

  • 1Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia.

Cells
|February 15, 2020
PubMed
Summary

Cancer cells evade death, promoting tumor growth. This review examines Smac-Mimetics (SMs) as a strategy to reinstate cell death, discussing their potential, synergy with other treatments, and challenges in cancer therapy.

Keywords:
IAPsSmac-MimeticsSmac/DIABLOTNFcancercell death

More Related Videos

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

7.6K
In Vitro Generation of Somite Derivatives from Human Induced Pluripotent Stem Cells
06:21

In Vitro Generation of Somite Derivatives from Human Induced Pluripotent Stem Cells

Published on: April 25, 2019

9.8K

Related Experiment Videos

Last Updated: Dec 28, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.6K
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

7.6K
In Vitro Generation of Somite Derivatives from Human Induced Pluripotent Stem Cells
06:21

In Vitro Generation of Somite Derivatives from Human Induced Pluripotent Stem Cells

Published on: April 25, 2019

9.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer cells evade apoptosis, a programmed cell death pathway, contributing to tumor progression.
  • Overexpression of Inhibitor of Apoptosis (IAP) proteins is a key mechanism cancer cells use to resist cell death.
  • Second mitochondria-derived activator of caspases (Smac/DIABLO) antagonists, known as Smac-Mimetics (SMs), are designed to counteract IAPs and promote cancer cell death.

Purpose of the Study:

  • To review the current applications of Smac-Mimetics (SMs) in cancer treatment.
  • To explore the potential of SMs to synergize with emerging cancer therapies.
  • To discuss the challenges and future prospects of SM-based cancer treatment strategies.

Main Methods:

  • Literature review of studies on Smac-Mimetics (SMs) in cancer therapy.
  • Analysis of clinical trial data for SMs in hematological and solid cancers.
  • Exploration of mechanisms of action and resistance to SMs.

Main Results:

  • Smac-Mimetics (SMs) have shown promise in preclinical and clinical settings but exhibit variable and limited efficacy in current trials.
  • SMs have the potential to enhance the effectiveness of other anti-cancer treatments through synergistic interactions.
  • Understanding resistance mechanisms is crucial for optimizing SM therapy.

Conclusions:

  • Smac-Mimetics (SMs) represent a promising therapeutic strategy for cancer by targeting IAP proteins and restoring apoptosis.
  • Further research and clinical investigation are needed to overcome current limitations and fully realize the potential of SMs in combination therapies.
  • Optimizing SM delivery, combination strategies, and patient selection will be key to improving outcomes in cancer treatment.